Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-30), HealthEquity's 14-Day RSI is 64.65.
The industry rank for HealthEquity's 14-Day RSI or its related term are showing as below:
FRA:2HE's 14-Day RSI is ranked worse than 95.13% of 698
companies
in the Healthcare Providers & Services industry
Industry Median: 48.685
vs FRA:2HE: 64.65
HealthEquity (FRA:2HE) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
HealthEquity 14-Day RSI Related Terms
FRA:2HE vs TEM, TXG, HNGE: 14-Day RSI Comparison
For the Health Information Services subindustry, HealthEquity's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthEquity 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthEquity's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where HealthEquity's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthEquity (FRA:2HE) has a 14-Day RSI of 64.65 as of Jul. 30, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on HealthEquity and its competitors. According to the industry distribution chart, HealthEquity ranks #664 out of 698 companies in the Healthcare Providers & Services industry, placing it in the top 95.1%.
Is HealthEquity's 14-Day RSI too high?
HealthEquity's current 14-Day RSI is 64.65. The Healthcare Providers & Services industry median 14-Day RSI is 48.69. HealthEquity's value of 64.65 is 32.8% above this industry median. Based on the distribution chart, HealthEquity ranks #664 out of 698 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, HealthEquity has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does HealthEquity's 14-Day RSI compare to TEM and TXG?
According to the Healthcare Providers & Services industry distribution chart, HealthEquity ranks #664 out of 698 companies for 14-Day RSI. This places HealthEquity in the lower half of its industry. The industry median 14-Day RSI is 48.69. HealthEquity's value of 64.65 is 32.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 48.69, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HealthEquity's current 14-Day RSI of 64.65 is 32.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on HealthEquity and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 48.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HealthEquity's current 14-Day RSI is 64.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthEquity stock overvalued right now?
HealthEquity (FRA:2HE) has a current 14-Day RSI of 64.65. The stock's GF Value™ is €86.84, compared to a current price of €87.00 — trading 0.2% above its estimated fair value. The current 14-Day RSI is 64.65 and 32.8% above the Healthcare Providers & Services industry median of 48.69. HealthEquity's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For HealthEquity (FRA:2HE), the current 14-Day RSI is 64.65 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthEquity (FRA:2HE) Overvalued in 2026?
Based on GuruFocus' analysis, HealthEquity stock appears to be overvalued.
The current stock price of €87.00 is trading 0.2% above its estimated GF Value™ of €86.84.
Key valuation signals for FRA:2HE:
14-Day RSI: 64.65
GF Value™: €86.84 vs. price of €87.00 (0.2% above fair value)
Industry Position: 32.8% above the Healthcare Providers & Services median (#664 of 698)
No single metric tells the full story. See the FRA:2HE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
95GF Score
Get the complete analysis for FRA:2HE
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2HE has been successfully added to your 
